- Home
- NUWE vs ITRM Comparison
NUWE vs ITRM Comparison
Compare NUWE & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- ITRM
- Stock Information
- Founded
- NUWE 1999
- ITRM 2015
- Country
- NUWE United States
- ITRM Ireland
- Employees
- NUWE N/A
- ITRM N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- ITRM Health Care
- Exchange
- NUWE Nasdaq
- ITRM Nasdaq
- Market Cap
- NUWE 3.9M
- ITRM 40.0M
- IPO Year
- NUWE N/A
- ITRM 2018
- Fundamental
- Price
- NUWE $4.02
- ITRM $0.68
- Analyst Decision
- NUWE
- ITRM Strong Buy
- Analyst Count
- NUWE 0
- ITRM 1
- Target Price
- NUWE N/A
- ITRM $9.00
- AVG Volume (30 Days)
- NUWE 189.0K
- ITRM 699.1K
- Earning Date
- NUWE 11-10-2025
- ITRM 11-13-2025
- Dividend Yield
- NUWE N/A
- ITRM N/A
- EPS Growth
- NUWE N/A
- ITRM N/A
- EPS
- NUWE N/A
- ITRM N/A
- Revenue
- NUWE $8,318,000.00
- ITRM N/A
- Revenue This Year
- NUWE $6.53
- ITRM N/A
- Revenue Next Year
- NUWE $51.63
- ITRM $482.25
- P/E Ratio
- NUWE N/A
- ITRM N/A
- Revenue Growth
- NUWE N/A
- ITRM N/A
- 52 Week Low
- NUWE $3.74
- ITRM $0.61
- 52 Week High
- NUWE $175.98
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- NUWE 31.47
- ITRM 42.56
- Support Level
- NUWE $3.74
- ITRM $0.66
- Resistance Level
- NUWE $5.23
- ITRM $0.76
- Average True Range (ATR)
- NUWE 0.32
- ITRM 0.05
- MACD
- NUWE 0.14
- ITRM 0.01
- Stochastic Oscillator
- NUWE 18.54
- ITRM 46.67
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.